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PaO2a b s t r a c t
Background: Lung volume reduction can be accomplished bronchoscopically, a procedure that represents
a potential alternative to LVRS.
Aim of the work: Evaluation of the role of the effectiveness of biological bronchoscopic lung volume reduc-
tion (BBLVR) in COPD patients.
Methods: 20 COPD patients were recruited for biological bronchoscopic lung volume reduction (BBLVR).
All patients were subjected to dyspnea grade, PaO2, FEV1% of predicted, size of bullae before and 2 weeks
after BBLVR.
Results: There was statistically significant improvement in dyspnea grade, PaO2, FEV1% of predicted, size
of bullae before and 2 weeks after BBLVR, with no detected complications.
Conclusion: Biological bronchoscopic lung volume reduction (BBLVR) is safe and effective in COPD
patients.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
COPD is defined as a preventable and treatable disease with
some significant extra pulmonary effects that may contribute to
the severity in individual patients. Its pulmonary component is
characterized by airflow limitation that is not fully reversible.
The airflow limitation is usually progressive and associated with
an abnormal inflammatory response of the lung to noxious parti-
cles or gases (1). Emphysema, or destruction of the gas exchanging
surfaces of the lung (alveoli), is a pathological term that is often
(but incorrectly) used clinically and describes only one of several
structural abnormalities present in patients with COPD [1].
Some studies [2,3] have indicated that lung volume reduction
surgery (LVRS) ameliorates dyspnea, increases exercise capacity,
improves lung function, enhances health-related quality of life
measures, and reduces mortality in selected patients with
advanced emphysema. Although beneficial to many patients with
emphysema, LVRS is associated with an operative mortality rateof 4 to 7%, a morbidity rate of 30% to 50%, and an average hospital
stay of 10 to 14 days [4].
There were several bronchoscopic procedures designed to
reduce lung volume in patients with emphysema. These include
one way valves, or bronchial occlusive devices to collapse emphy-
sematous regions of lung and bronchial fenestration with bypass
stents to improve expiratory flow [5].
Bronchoscopic biological lung volume reduction (BBLVR) is a
minimally invasive procedure based on tissue engineering princi-
ples, was performed for first time in six sheep with papain-
induced experimental emphysema [6].
Lung volume reduction can be accomplished bronchoscopically,
a procedure that represents a potential alternative to LVRS.Objective
Evaluation of the safety and e effectiveness of BBLVR in COPD
patients.Materials and methods
20 COPD patients were recruited for biological bronchoscopic
lung reduction during the period between November 2014 and
August 2016.onary
Table 1




BBLVR (n = 20)
P value
Dyspnea Grade
Grade II 0(0%) 2(10%) 0.027⁄
2 M.E. Atta et al. / Egyptian Journal of Chest Diseases and Tuberculosis xxx (2016) xxx–xxxAll patients were subjected to the following: full history taking.,
thorough clinical examination, pre and 2 weeks post BBLVR
spirometer (FEV1%),pre and 2 weeks post BBLVR PaO2 and pre
and 2 weeks post BBLVR radiological assessment by plain chest X
ray poster anterior view and high resolution computed tomogra-
phy (CT) chest.
Informed consent was taken from all subjects after clear expla-
nation of the benefit of the research and information about any risk
or discomfort during the research.
Inclusion criteria:
 Clinical and CT diagnosis of emphysematous bulla or bullae.
 Persistent dyspnea inspite of at least 4 weeks of appropriate
medical therapy.
 FEV1 < 45% predicted.
 PaO2P 60 mmHg on nasal prong 64 L per minute.
 PaCO2 < 60 mmHg.
Exclusion criteria:
 Associated pulmonary comorbidities.
 Medical condition associated with high risk bronchoscope as:
1. Life threatening arrhythmia.
2. Severe hypoxemia.
3. Bleeding tendency that can’t be corrected.
4. Severe airway obstruction.
 FEV1 < 20% predicted.
BLVR procedure: BLVR was done under local anesthesia (lido-
caine spray 10%) with supplemental oxygen using nasal catheter
during the procedure.
Video bronchoscope (Pentax) was introduced through nostril.
The bronchoscope was advanced to reach the targeted segment
of the bronchial tree that was recognized by chest X ray and high
resolution CT chest, then the bronchoscope wedged to the targeted
segmental bronchi. A small catheter gauged(4 mm) was introduced
through the working channel of the bronchoscope, when its tip
appeared about 1 cm beyond the tip of bronchoscope, 10 ml of
autologous blood and 5 ml tranexamic acid (cyclokapron concen-
tration 100 mg/ml)injected, then the prepared gel foam was also
injected through the catheter. [The gel piece which is a water insol-
uble material that was cut into tiny pieces and normal saline could
be added to the pieces to form the gel foam].
The bronchoscope was left in wedge position for 1 to 2 min till
the coagulation process completed. (Normal clotting time 2–9 min
was accelerated by adding the cyclokapron), and to prevent
regurgitation of the blood and foam.
The gel foam led to obstruction of the targeted segment, while
the blood trickling on the wall of the bulla lead to shrinkage and
collapse of the bulla as it coagulated.
Sedative drugs were avoided before the bronchoscope to avoid
respiratory center depression. Cough suppressant was given before
and after the procedure.Grade III 6(30%) 12(60%)
Grade IV 14(70%) 6(30%)
PaO2
Min.-Max 58–65 60–70 <0.001⁄
Mean ± SD 61.20 ± 2.285 66.50 ± 2.911
FEV1%of predicted
Min.-Max 25.7–43.5 32.4–48.7 <0.001⁄
Mean ± SD 33.170 ± 5.415 38.66 ± 5.090
CXR (size of bullae)
Min.-Max 3–7 3–6 <0.001⁄
Mean ± SD 5.20 ± 1.105 4.50 ± 0.827
HRCT (size of bullae)
Min.-Max 8–18 4–10 <0.001⁄
Mean ± SD 12.70 ± 3.278 7.60 ± 1.903
Significant between groups P < 0.05.Results
This study was conducted on twenty patients, all the studied
group of patients were male and the age ranged between
49–70 years with a mean of 60.30 ± 5.430.
There were emphysematous bulla or bullae (9 patients with sin-
gle unilateral bulla and 11 with multiple bilateral bullae).
Table 1 shows that the Regarding to the dyspnea of the studied
group of patients, there were 6(30%) patients presented with exer-
tional dyspnea Grade III and 14(70%) patients presented with exer-
tional dyspnea Grade VI before BBLVR, 2 weeks after BBLVR, 2(10%)Please cite this article in press as: M.E. Atta et al., The use of biological bronch
disease patients, Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/10.1016/patients presented with exertional dyspnea Grade II, 12(60%)
patients presented with exertional dyspnea Grade III and 6(30%)
patients presented with exertional dyspnea Grade VI with statisti-
cally significant improvement in dyspnea grade as P value is 0.027.
Regarding PaO2, before BBLVR, it ranged between 58–65with a
mean of 61.20 ± 2.285 and 2 weeks after BBLVR it ranged between
60–70with a mean of 66.50 ± 2.911 with statistically significant
improvement in PaO2 as P value is <0.001.
Regarding FEV1% predicted, before BBLVR, it ranged between
25.7–43.5 with a mean of 33.170 ± 5.415 and 2 weeks after BBLVR
it ranged between 32.4–48.7 with a mean of 38.66 ± 5.090 with
statistically significant improvement in FEV1%of predicted as P
value is <0.001.
Regarding CXR (size of bullae), Before BBLVR, it ranged between
3–7 cm with a mean of 5.20 ± 1.105 and 2 weeks after BBLVR it
ranged between 3–6 cm with a mean of 4.50 ± 0.827 with statisti-
cally significant improvement in CXR (size of bullae) as P value is
<0.001.
Regarding HRCT (size of bullae), Before BBLVR, it ranged
between 8–18 cm with a mean of 12.70 ± 3.278 and 2 weeks after
BBLVR it ranged between 4–10 cmwith a mean of 7.60 ± 1.903with
statistically significant improvement in HRCT (size of bullae) as P
value is < 0.001.
In this study all patients were discharged from the hospital in
the same day of BBLVR treatment. No serious adverse events were
observed in any patient during or after BBLVR therapy. Adverse
events were minor and transient, and most of them were likely
attributable to the bronchoscope. They included cough in 2(10%)
patients, sore throat in 1(5%) patient and blood streaked sputum
from the injected blood in 4(20%) patients.Discussion
Lung volume reduction surgery (LVRS) was done to improve
pulmonary function, quality of life, and exercise tolerance. Survival
after LVRS is approximating 90% at 1 year, 77% at 3 years, and 65%
at 5 years. Exercise capacity also improves after LVRS with the six
minute walk distance increasing 6 months after surgery. Patients
undergoing LVRS also showed sustained improvement in general
(Quality of Well-Being score) and health related (St. George’s Res-
piratory Questionnaire) quality of life, as well as improved noctur-
nal sleep quality and neurobehavioral functioning [7].
Medical therapy has always been the main stay of treatment for
emphysema. New devices and techniques were developed recently
to achieve total bronchoscopic approach of LVR. The main potential
benefit of these nonsurgical approaches is reduced morbidity withoscopic lung volume reduction therapy in chronic obstructive pulmonary
j.ejcdt.2016.10.013
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comorbidities [8].
The other concept of bronchoscopic Lung volume reduction
(BLVR) could be achieved by inducing volume reduction with sea-
lants, endobronchial occluders, and endobronchial valves (EBV)
that only allows air to flow out in the direction of expiration. These
EBVs are very expensive and not available in many countries [9].
As the results of devices used in BLVR still not satisfactory, so
treatment could be done by bronchoscopic administration of a
hydrogel of thrombin and fibrinogen or autologous blood that
flows into the alveolar compartment which called bronchoscopic
biological lung volume reduction (BBLVR) [10].
This study was conducted on twenty patients with emphysema-
tous bulla or bullae (9 patients with single unilateral bulla and 11
with multiple bilateral bullae). Chest X ray and high resolution CT
chest were used to detect the site and size of the bulla and autol-
ogous blood and gel foam were the material used for BBLVR and
this method led to highly significant reduction of bullae size in
80% of patients, significant improvement of PFT regarding FEV1%,
PaO2 and also significant improvement of dyspnea grade.
Regarding the size of the bullae, the results achieved in this
study revealed significant reduction in the mean size of the bullae
(p 6 0.001) in all patients after BBLVR.
Refaely et al. [11] recruited 25 patients and used hydrogel of
thrombin and fibrinogen to asses BLVR in advanced homogenous
emphysema and proved that atelectatic bands were observed in
the high resolution CT chest of 47% of the selected patients after
BBLVR.
The present study agreed with results that were achieved by
Criner et al. [12] who used hydrogel of thrombin and fibrinogen
to asses BBLVR in advanced heterogenous emphysema and
reported that scaring lines were observed in 57% of low dose
(LD) treatment (10 ml of the biological material) and 68% of high
dose (HD) treatment (20 ml of the hydrogel).
The autologous blood that was used in this study led to shrink-
age of the bulla, tranexamic acid accelerated the coagulation and
the gel foam led to blockage of the affected subsegment and the
hydrogel which was used by Reilly et al. [10] Criner et al. [12]
and Refaely et al. [11] led to atelectasis of the targeted segment
so they may overcome the problem of collateral ventilation unlike
the one way valves used by Venuta et al. [7] which affected more
by the collateral ventilation.
Moreover, the achieved results in this study regarding FEV1%
(significant rise of FEV1% after BBLVR), these results are going with
the results that were achieved by Refaely et al. [11] who stated that
there was significant rise of FEV1% only in high dose (HD) treat-
ment (11%), also with the results that were achieved by Criner
et al. [12] who stated that there was rise of FEV1% for 11% and Reilly
et al. [10] who reported that there were no clinically significant
changes were observed in FEV1 after BBLVR. Furthermore, The
achieved results in this study agreed with those obtained by Hop-
kinson et al. [13], Wan et al. [14] and Venuta et al. [7] who reported
that the rises of FEV1% were (3%),(10.7%) and (11%) respectively
although they all used the expensive EBVS.
The obtained results in this study regarding the grade of dyspnea
(significant decrease in the dyspnea grade after BBLVR) these
results are comparable to the achieved results by Refaely et al.
[11] who proved that there was 1 unit decline in MRCD score after
BBLVR, Criner et al., [12] and Reilly et al. [10] who stated that signif-
icant improvement in MRCD score occurred when higher dose of
hydrogel used in BBLVR (P 6 0.001). More over, Venuta et al. [7] sta-
ted that MRCD score improved after BLVR from 4 to 2 (P 6 0.004).
The achieved results in this study regarding PaO2 (highly signif-
icant increase of PaO2 after BBLVR),these results match with the
achieved results by Venuta et al. [7] who stated that significant rise
of PaO2 was observed after BBLVR and most of the patients (67%)Please cite this article in press as: M.E. Atta et al., The use of biological bronch
disease patients, Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/10.1016/required less supplemental oxygen. In contrast, Reilly et al. [10]
reported that there was no consistent change in arterial blood
gas value or supplemental oxygen usage following BBLVR.
In this study all patients were discharged from the hospital in
the same day of BBLVR treatment. No serious adverse events were
observed in any patient during or after BBLVR therapy. Adverse
events were minor and transient, and most of them were likely
attributable to the bronchoscope. They included cough, sore throat
and blood streaked sputum from the injected blood, this matched
with the multicenteric studies done by Refaely et al. [11], Criner
et al. [12] and Reilly et al. [10] in which there were no deaths or
serious medical complications during the study.
Moreover, Refaely et al. 2009 [11] stated that safety profile of
BBLVR reported in advanced emphysema compared favorably to
LVRS and other endobronchial lung volume reduction techniques,
no deaths or serious medical complications were observed.
In contrast, Venuta et al. [7] observed complications in 3
patients (23% of the patients), contralateral pneumothorax devel-
oped 15 days post procedure while the patient was at home, bilat-
eral simultaneous pneumothoraces occurred 2 and 7 days post
procedure. One patient had pneumonia. Patients with complica-
tions need hospitalization till stabilization of the condition. Also
Hopkinson et al. [13] stated that two patients, both of whom had
radiological evidence of volume reduction, developed ipsilateral
pneumothoraces.
Criner, et al. [12] stated that serious pulmonary and cardiovas-
cular complications within 30 days of treatment have been
reported in up to 49% of LVRS patients.
From this study it was concluded that Bronchoscopic biological
lung volume reduction therapy using autologous blood and gel-
foam was well tolerated and safe in patients with advanced
emphysematous bulla. Treatment at diseased sites is associated
with modest improvement in pulmonary function test values,
PaO2, reduced bullae size and reduced dyspnea.
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